Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Surrogate endpoints in advanced sarcoma trials: a meta-analysis.

Savina M, Litière S, Italiano A, Burzykowski T, Bonnetain F, Gourgou S, Rondeau V, Blay JY, Cousin S, Duffaud F, Gelderblom H, Gronchi A, Judson I, Le Cesne A, Lorigan P, Maurel J, van der Graaf W, Verweij J, Mathoulin-Pélissier S, Bellera C.

Oncotarget. 2018 Oct 2;9(77):34617-34627. doi: 10.18632/oncotarget.26166. eCollection 2018 Oct 2.

2.

A Review of Studies Examining the Relationship between Progression-Free Survival and Overall Survival in Advanced or Metastatic Cancer [Internet].

Davis S, Tappenden P, Cantrell A.

London: National Institute for Health and Care Excellence (NICE); 2012 Aug.

3.

Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.

Foster NR, Qi Y, Shi Q, Krook JE, Kugler JW, Jett JR, Molina JR, Schild SE, Adjei AA, Mandrekar SJ.

Cancer. 2011 Mar 15;117(6):1262-71. doi: 10.1002/cncr.25526. Epub 2010 Oct 19.

4.

Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review.

Savina M, Gourgou S, Italiano A, Dinart D, Rondeau V, Penel N, Mathoulin-Pelissier S, Bellera C.

Crit Rev Oncol Hematol. 2018 Mar;123:21-41. doi: 10.1016/j.critrevonc.2017.11.014. Epub 2017 Nov 23. Review.

PMID:
29482777
5.

Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.

Franklin J, Eichenauer DA, Becker I, Monsef I, Engert A.

Cochrane Database Syst Rev. 2017 Sep 13;9:CD008814. doi: 10.1002/14651858.CD008814.pub2. Review.

PMID:
28901021
6.

Potential surrogate endpoints for overall survival in locoregionally advanced nasopharyngeal carcinoma: an analysis of a phase III randomized trial.

Chen YP, Chen Y, Zhang WN, Liang SB, Zong JF, Chen L, Mao YP, Tang LL, Li WF, Liu X, Guo Y, Lin AH, Liu MZ, Sun Y, Ma J.

Sci Rep. 2015 Jul 29;5:12502. doi: 10.1038/srep12502.

7.

Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers.

Ciani O, Davis S, Tappenden P, Garside R, Stein K, Cantrell A, Saad ED, Buyse M, Taylor RS.

Int J Technol Assess Health Care. 2014 Jul;30(3):312-24. doi: 10.1017/S0266462314000300. Review.

8.

Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer.

Ciani O, Buyse M, Garside R, Peters J, Saad ED, Stein K, Taylor RS.

J Clin Epidemiol. 2015 Jul;68(7):833-42. doi: 10.1016/j.jclinepi.2015.02.016. Epub 2015 Mar 6. Review.

9.

Evolution of Randomized Trials in Advanced/Metastatic Soft Tissue Sarcoma: End Point Selection, Surrogacy, and Quality of Reporting.

Zer A, Prince RM, Amir E, Abdul Razak A.

J Clin Oncol. 2016 May 1;34(13):1469-75. doi: 10.1200/JCO.2015.64.3437. Epub 2016 Mar 7. Review.

PMID:
26951308
10.
11.

The value of surrogate endpoints for predicting real-world survival across five cancer types.

Shafrin J, Brookmeyer R, Peneva D, Park J, Zhang J, Figlin RA, Lakdawalla DN.

Curr Med Res Opin. 2016;32(4):731-9. doi: 10.1185/03007995.2016.1140027. Epub 2016 Jan 25.

PMID:
26743800
12.

Assessment of Correlation Between Early and Late Efficacy Endpoints to Identify Potential Surrogacy Relationships in Non-Hodgkin Lymphoma: a Literature-Based Meta-analysis of 108 Phase II and Phase III Studies.

Zhu R, Lu D, Chu YW, Chai A, Green M, Zhang N, Jin JY.

AAPS J. 2017 May;19(3):669-681. doi: 10.1208/s12248-017-0056-x. Epub 2017 Feb 21. Review.

PMID:
28224402
13.

Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis.

Rotolo F, Pignon JP, Bourhis J, Marguet S, Leclercq J, Tong Ng W, Ma J, Chan AT, Huang PY, Zhu G, Chua DT, Chen Y, Mai HQ, Kwong DL, Soong YL, Moon J, Tung Y, Chi KH, Fountzilas G, Zhang L, Hui EP, Lee AW, Blanchard P, Michiels S; MAC-NPC Collaborative Group.

J Natl Cancer Inst. 2017 Apr;109(4). pii: djw239.

14.

Surrogate endpoints for overall survival in lung cancer trials: a review.

Fiteni F, Westeel V, Bonnetain F.

Expert Rev Anticancer Ther. 2017 May;17(5):447-454. doi: 10.1080/14737140.2017.1316196. Epub 2017 Apr 12. Review.

PMID:
28399678
15.

Progression-free survival as surrogate endpoint in advanced pancreatic cancer: meta-analysis of 30 randomized first-line trials.

Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Barni S.

Hepatobiliary Pancreat Dis Int. 2015 Apr;14(2):124-31. Review.

PMID:
25865683
16.

Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials.

Li L, Pan Z.

Clin Breast Cancer. 2018 Feb;18(1):63-70. doi: 10.1016/j.clbc.2017.07.015. Epub 2017 Jul 25.

PMID:
28818493
17.

Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.

Wang X, Wang X, Hodgson L, George SL, Sargent DJ, Foster NR, Ganti AK, Stinchcombe TE, Crawford J, Kratzke R, Adjei AA, Kindler HL, Vokes EE, Pang H.

Oncologist. 2017 Feb;22(2):189-198. doi: 10.1634/theoncologist.2016-0121. Epub 2017 Feb 10.

18.

Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2- metastatic breast cancer.

Forsythe A, Chandiwana D, Barth J, Thabane M, Baeck J, Tremblay G.

Breast Cancer (Dove Med Press). 2018 May 4;10:69-78. doi: 10.2147/BCTT.S162841. eCollection 2018.

19.

Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data.

Mauguen A, Pignon JP, Burdett S, Domerg C, Fisher D, Paulus R, Mandrekar SJ, Belani CP, Shepherd FA, Eisen T, Pang H, Collette L, Sause WT, Dahlberg SE, Crawford J, O'Brien M, Schild SE, Parmar M, Tierney JF, Le Pechoux C, Michiels S; Surrogate Lung Project Collaborative Group.

Lancet Oncol. 2013 Jun;14(7):619-26. doi: 10.1016/S1470-2045(13)70158-X. Epub 2013 May 14.

20.

Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials.

Shitara K, Ikeda J, Yokota T, Takahari D, Ura T, Muro K, Matsuo K.

Invest New Drugs. 2012 Jun;30(3):1224-31. doi: 10.1007/s10637-011-9648-y. Epub 2011 Feb 25.

PMID:
21350803

Supplemental Content

Support Center